Trevi Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Trevi Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to 2023.
  • Trevi Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$13.2M, a 72% decline year-over-year.
  • Trevi Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$44.3M, a 65.7% decline year-over-year.
  • Trevi Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$29.1M, a 0.3% increase from 2022.
  • Trevi Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$29.2M, a 14.1% increase from 2021.
  • Trevi Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$33.9M, a 3.61% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$29.1M +$87K +0.3% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-20
2022 -$29.2M +$4.79M +14.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-20
2021 -$33.9M -$1.18M -3.61% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-16
2020 -$32.8M -$6.71M -25.8% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-17
2019 -$26.1M -$5.51M -26.8% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
2018 -$20.5M Jan 1, 2018 Dec 31, 2018 10-K 2020-03-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.